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INTRODUCTION
Bevacizumab was shown to improve the overall survival (OS) time, progression-free survival (PFS) time, and objective response rate (RR) in a placebo-controlled phase III trial when added to irinotecan, fluorouracil, and leucovorin (IFL) chemotherapy in the first-line treatment of metastatic colorectal cancer (mCRC) [1] . An exploratory analysis of this study suggested that the OS benefit of the addition of bevacizumab was independent of the mutation status of K-ras, B-raf, or p53 [2] . The selection of K-ras for these analyses was based upon evidence that K-Ras regulates vascular endothelial growth factor (VEGF) and other angiogenic factors [3, 4] , as well as numerous reports that K-ras is a negative prognostic factor in patients with mCRC [5] [6] [7] [8] .
Mutations in K-ras strongly predict for a lack of response to anti-epidermal growth factor receptor (EGFR) antibodies [9 -12] . For this reason, K-ras testing is required by the European Medical Authority for the use of panitumumab and cetuximab. The role of ras mutations in predicting response to traditional cytotoxic agents in advanced CRC has not been well studied.
The impact of ras mutations on OS was previously reported for the addition of bevacizumab to first-line IFL chemotherapy. To better describe the clinical benefit of bevacizumab according to K-ras mutation status in this patient population, we performed additional analyses of other measures of clinical benefit, including the PFS time and RR.
METHODS

Patients and Study Design
The details of study AVF2107 (registered at http://www. ClinicalTrials.gov, ID number NCT00109070), including patient eligibility criteria, study design, treatment, and assessments, have been reported previously [1] . Only patients with sufficient tumor tissue for molecular assessment of K-ras were included in the exploratory analyses contained in this report.
Ethics
The institutional review boards of the investigative centers approved the study protocol, and the trial was conducted in accordance with the Declaration of Helsinki, U.S. Food and Drug Administration Good Clinical Practices, and local ethical and legal requirements. All patients provided written informed consent for their study participation.
Molecular Testing of Tumor Tissue
The details of the available tissue samples, laser capture microdissection, polymerase chain reaction (PCR) primers and conditions, and direct sequencing of PCR products have been described previously [2] . The selected primers covered codons 12 and 13.
Statistical Analyses
The efficacy analysis was based on randomized patients with known K-ras mutation status. The PFS time was defined as the time from randomization to disease progression or death resulting from any cause during first-line treatment. Median PFS times were estimated using the KaplanMeier method. An unstratified Cox regression model was used to estimate the hazard ratio (HR) for the bevacizumab group relative to the control group. A two-sided log-rank test (␣ ϭ 0.05) was used to compare the differences between the bevacizumab and the placebo group. Because of sample size considerations, this test was unstratified. The objective RR was defined as the rate of a complete or partial response determined on two consecutive occasions at least 4 weeks apart during first-line treatment. The 2 test was used to compare the objective RRs. Any differential effect of treatment between the K-ras mutation status groups was evaluated using a Cox model with K-ras mutation status, treatment, and the Kras-by-treatment interaction term in the model.
RESULTS
Tissue samples from 230 of 813 patients (28%) were available for molecular analysis of the selected K-ras codons. Of these 230 patients, 129 had been randomly assigned to receive IFL chemotherapy plus bevacizumab (IFL ϩ BV) and 101 had been randomly assigned to receive IFL chemotherapy plus placebo (IFL ϩ placebo). Demographic and baseline disease characteristics for the K-ras subgroup and for the overall phase III study population are summarized in Table 1 . The median ages in the groups were 62.0 and 58.0 years, respectively. The demographic and baseline characteristics were similar in the subset of patients with available tumor tissue and the entire study population [1] . A higher incidence of patients with an Eastern Cooperative Oncol-ogy Group performance status score of zero in the placebo arm (61.4% versus 55.2%) and a shorter mean time from diagnosis in both arms of the subpopulation (12.4 months for IFL ϩ placebo and 13.2 months for IFL ϩ BV in the tissue available subgroup versus 16.1 months for IFL ϩ placebo and 15.2 months for IFL ϩ BV in the study as a whole) were observed. Additional characteristics not included in Table 1 , that is, gender, race/ethnicity, body weight and surface area, and serum lactate dehydrogenase, were comparable with those in the entire population. K-ras mutations were detected in 78 of the 230 patients (34%).
Measures of clinical benefit were generally comparable in the subgroup with available tissue and in the overall population. Comparing the subgroup with available tissue with the overall population, the HRs for OS were similar (HR, 0. 
Prognostic Value of K-ras Mutations in mCRC
To assess the prognostic importance of K-ras, PFS was compared according to K-ras status for both the IFL ϩ placebo and the IFL ϩ BV groups (Fig. 1) . For patients treated with IFL ϩ placebo, the median PFS duration was 7.4 months for wildtype (wt)-K-ras patients and 5.5 months for mutant (m)-K-ras patients (HR, 0.69; 95% CI, 0.44 -1.08; p ϭ .11 for wt-K-ras versus m-K-ras). In patients treated with IFL ϩ BV, the median PFS was 13.5 months for wt-K-ras patients and 9.3 months for m-K-ras patients (HR, 0.66; 95% CI, 0.41-1.08; p ϭ .09 for wt-K-ras versus m-K-ras).
PREDICTIVE VALUE OF K-RAS MUTATIONS FOR TREATMENT WITH BEVACIZUMAB IN MCRC
Results of the analyses of OS, PFS, and RR according to K-ras mutation status are listed in Table 2 . Kaplan-Meier curves for OS and PFS are shown in Figure 2 and Figure 3 , respectively. In both the wt-K-ras and m-K-ras groups, the addition of bevacizumab to IFL chemotherapy resulted in a statistically significant longer PFS time, with comparable HRs for progression. In the wt-K-ras group, the median PFS duration was 13.5 months for IFL ϩ BV versus 7.4 months for IFL ϩ placebo (HR, 0.44; 95% CI, 0.29 -0.67; p Ͻ .0001). For the m-K-ras group, the median PFS duration was 9.3 months for IFL ϩ BV versus 5.5 months for IFL ϩ placebo (HR, 0.41; 95% CI, 0.24 -0.70; p ϭ .0008). As previously reported [2] , comparable findings were noted for OS. In the wt-K-ras group, the median OS time was 27.7 months for IFL ϩ BV versus 17.6 months for IFL ϩ placebo (HR, 0.58; 95% CI, 0.34 -0.99; p ϭ .04). For the m-Kras group, the median OS time was 19.9 months for IFL ϩ BV versus 13.6 months for IFL ϩ placebo (HR, 0.69; 95% CI, 0.37-1.31; p ϭ .26). For PFS and OS, the point estimates for the interaction effect suggest that there is no dif- ference in the treatment benefit between the K-ras subgroups (data not shown); however, wide CIs for these estimates indicate limited statistical power to detect a clinically meaningful differential effect. Regarding tumor response, the overall RRs for IFL ϩ BV versus IFL ϩ placebo were 60.0% versus 37.3% in the wt-K-ras group (p ϭ .006) and 43.2% versus 41.2% in the m-K-ras group (p ϭ .86), respectively.
The incidences of bevacizumab-associated adverse events and any grade 3 or 4 adverse events (based on the National Cancer Institute -Common Toxicity Criteria) were comparable for the two K-ras subgroups (Table 3) , despite the longer time on treatment for the wt-K-ras subgroup compared with the m-K-ras subgroup (and for the bevacizumab group compared with the placebo group). Because of the limited size of the subgroup with tissue available for K-ras analysis and the low rates of most grade Ն3 adverse events and events of special interest regarding bevacizumab, small event rate differences between the m-K-ras and wt-K-ras groups cannot be excluded.
DISCUSSION
A growing body of evidence suggests not only that mutations of the K-ras oncogene have prognostic significance in mCRC, but also that K-ras mutations may serve as predictive markers that can be used to guide the use of anti-EGFR therapy. Multiple phase II and III studies have demonstrated that patients with mCRC harboring mutations in K-ras do not appear to derive clinical benefit from anti-EGFR monoclonal antibody treatment, when used either as monotherapy or in combination with cytotoxic chemotherapy [9 -16].
Several reports have indicated that K-ras mutations are negative prognostic markers and portend a poorer outcome in mCRC [7, 8, 17] . The retrospective analysis presented in this report appears to support the prognostic significance of K-ras mutations in mCRC. This finding is consistent with previously reported data involving cytotoxic chemotherapies that generally support the concept that K-Ras is not a predictive marker for benefit, or lack of benefit, from traditional cytotoxic chemotherapy [5] [6] [7] . More recent data [10 -12] , however, suggest that K-ras status is not generally prognostic and may have a modest but distinct predictive importance for oxaliplatin versus irinotecan regimens. Thus, the question of the prognostic significance of mutated K-ras in mCRC appears to remain open.
Independent of whether K-ras status is prognostic in mCRC, the data in the current report strongly suggest that K-ras status does not predict clinical benefit from the addition of bevacizumab to first-line IFL chemotherapy. The relative benefits in terms of PFS and OS associated with the addition of bevacizumab to IFL chemotherapy were comparable in the m-K-ras and wt-K-ras groups.
Whereas patients with wt-K-ras in this study appeared to have a greater RR with the addition of bevacizumab to IFL, no such benefit was found in patients with m-K-ras.
Multiple preclinical studies have demonstrated that Kras mutations upregulate VEGF and numerous other angiogenic factors in tumor cells [3, 4, 18] . Given these potential mechanisms of resistance, the same clinical benefit from bevacizumab in patients with m-K-ras and wt-K-ras tumors supports the role of VEGF as the primary angiogenic factor in CRC. This analysis has several limitations. First, it is retrospective, so tissue was not available for the assessment of K-ras for a significant proportion of the study population; thus, an unintentional selection bias for the subset of patients included in this analysis is possible. However, the patient and tumor characteristics for the subgroup of patients with available tissue were comparable with those of the overall study population and the frequency and type of Kras mutations in this study were similar to those from other reports [7] [8] [9] [10] 17] . The relatively small sample size in this study also precludes a definitive assessment of the presence or absence of an interaction. A definitive study that could detect an HR of 0.6 in the wt-K-ras group and an HR of one in the m-K-ras group with 80% power would require 540 events and potentially Ͼ1,000 subjects.
These data have implications for the appropriate management of patients with mCRC as well as the design and interpretation of clinical trials in this disease. Our analyses suggest that the clinical benefit from the anti-VEGF therapy bevacizumab, unlike EGFR-targeted antibodies, appears to be independent of K-ras status. At a practical level, K-ras testing is unnecessary to determine which patients should receive bevacizumab. These data also highlight the complexity of K-ras biology in mCRC. Clinical trial populations need to be defined regarding the selection, or lack of selection, for K-ras mutation status in order to allow for appropriate interpretation.
Lastly, these data also highlight the distinction between prognostic and predictive markers, a topic that has been extensively reviewed [19] . As diagnostics and therapeutics related to key oncogenes become available, these distinctions will take on even greater clinical significance.
